GQG Partners
NVO

GQG Partners’s Novo Nordisk NVO Stock Holding History

GQG Partners’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,923
Closed -$409K – 101
2025
Q2 		$409K Sell
5,923
-111,202
-95% -$7.56M ﹤0.01% 86
2025
Q1 		$8.13M Sell
117,125
-12,877,408
-99% -$1.06B 0.01% 62
2024
Q4 		$1.12B Buy
12,994,533
+5,556,460
+75% +$601M 1.66% 22
2024
Q3 		$886M Buy
7,438,073
+3,223,857
+76% +$430M 1.39% 28
2024
Q2 		$602M Buy
4,214,216
+581,152
+16% +$77M 0.91% 30
2024
Q1 		$466M Buy
3,633,064
+3,151,584
+655% +$375M 0.75% 30
2023
Q4 		$49.8M Buy
481,480
+75,344
+19% +$7.45M 0.11% 42
2023
Q3 		$36.9M Buy
406,136
+17,046
+4% +$1.5M 0.09% 42
2023
Q2 		$31.5M Sell
389,090
-59,232
-13% -$4.84M 0.07% 39
2023
Q1 		$35.7M Buy
448,322
+55,158
+14% +$3.91M 0.09% 42
2022
Q4 		$26.6M Buy
393,164
+23,350
+6% +$1.37M 0.07% 53
2022
Q3 		$18.4M Buy
369,814
+97,574
+36% +$5.23M 0.05% 50
2022
Q2 		$15.2M Sell
272,240
-29,654
-10% -$1.65M 0.04% 50
2022
Q1 		$16.8M Buy
301,894
+11,420
+4% +$586K 0.04% 48
2021
Q4 		$16.3M Buy
290,474
+60,614
+26% +$3.28M 0.04% 54
2021
Q3 		$11M Buy
229,860
+5,138
+2% +$248K 0.03% 48
2021
Q2 		$9.41M Sell
224,722
-17,344
-7% -$672K 0.03% 46
2021
Q1 		$8.16M Sell
242,066
-25,894
-10% -$922K 0.03% 50
2020
Q4 		$9.36M Buy
267,960
+211,182
+372% +$7.3M 0.03% 51
2020
Q3 		$1.97M Buy
56,778
+1,690
+3% +$56.3K 0.01% 59
2020
Q2 		$1.8M Sell
55,088
-1,626
-3% -$51.9K 0.01% 54
2020
Q1 		$1.71M Buy
56,714
+42,132
+289% +$1.25M 0.01% 51
2019
Q4 		$422K Buy
+14,582
New +$404K ﹤0.01% 47
2018
Q1 		– Sell
-20,400
Closed -$547K – 59
2017
Q4 		$547K Hold
20,400
– – 0.02% 50
2017
Q3 		$491K Hold
20,400
– – 0.02% 52
2017
Q2 		$437K Buy
+20,400
New +$412K 0.03% 47

Other funds holding NVO

Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $42.5B AUM 18.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

GQG Partners's NVO Position: Q3 2025 in Review

GQG Partners sold out of Novo Nordisk (NVO) in Q3 2025, closing a stake of 5,923 shares — an estimated $409K sold.

GQG Partners first reported a position in NVO in Q2 2017 and held it in 26 quarters. The position peaked at $1.12B in Q4 2024. 1,398 funds tracked by Wall St. Rank hold NVO as of Q3 2025.

  • GQG Partners reported no remaining Novo Nordisk position as of Q3 2025 after selling out during the quarter.
  • GQG Partners sold 5,923 Novo Nordisk shares in Q3 2025, an estimated $409K.
  • GQG Partners first reported a position in Novo Nordisk in Q2 2017 and held it in 26 quarters.
  • GQG Partners's Novo Nordisk position peaked at $1.12B in Q4 2024.
  • 1,398 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.

Based on GQG Partners's 13F filing for Q3 2025, filed 13 Nov 2025.